Clinical Development

Aastrom is dedicated to treating patients with severe, chronic cardiovascular diseases through the use of multicellular therapy expanded from the patient’s own bone marrow. In keeping with our mission and values, we use rigorous scientific methods to meet our ultimate goal of treating human disease and relieving human suffering. A necessary part of that process is conducting clinical trials. Aastrom currently is in clinical development for two cardiovascular diseases, critical limb ischemia (CLI) and dilated cardiomyopathy (DCM).

• CLI Clinical Trials: We currently have two clinical trials for critical limb ischemia, one in Phase 2 and one in Phase 3. The Phase 2 trial is completed and is the process of data analysis; the Phase 3 trial is in development and will be enrolling soon. Learn more about CLI clinical trials.
• DCM Clinical Trials: We are also conducting two clinical trials for dilated cardiomyopathy, both in Phase 2a. Both are active trials but are not currently enrolling patients. Learn more about DCM clinical trials.

You may also visit ClinicalTrial.gov, a registry of federally and privately supported clinical trials conducted in the United States and around the world, or contact us with questions about our clinical development process.

Clinical Development Pipeline